1
Participants
Start Date
April 30, 2025
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2026
GCAR1
GCAR 1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector containing a chimeric antigen receptor (CAR) that enables the specific targeting towards tumor cells expressing the cell surface protein glycoprotein non-metastatic B (GPNMB).
AHS Cancer Control Alberta
OTHER